Russian drugmaker Nanolek eyes more active foreign expansion in coming years

15 October 2019

Russian drugmakers are considering more active foreign expansion that will be in the form of larger exports of their products, according to recent statements of producers and industry analysts, reports The Pharma Letter’s local correspondent.

For example, such plans have been recently announced by Nanolek, a leading Russian producer of vaccines, which several weeks ago completed registration of three drugs, with the aim of their further exports to Azerbaijan and other countries of the post-Soviet space.

Among these drugs are the antiallergenic Nalorius (desloratadine), as well as two drugs for the treatment of cardiovascular diseases - Ramipril-Nanolek and Nebivolol-Nanolek.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK